Imagine a world where diseases could be cured by tricking cells into destroying their own harmful proteins. Sounds like science fiction, right? But this is exactly what researchers are now closer to achieving with a groundbreaking discovery in molecular biology.
Our cells are like tiny, efficient factories, constantly producing and recycling proteins. When proteins outlive their usefulness, they’re tagged for disposal by a sophisticated waste-management system. Scientists have long dreamed of hijacking this system to target disease-causing proteins, and recent advancements in drug discovery are turning this dream into reality. The secret weapon? Molecular glues—tiny molecules that act like matchmakers, forcing proteins to interact in ways they normally wouldn’t. By bringing a harmful protein into contact with a cellular degradation enzyme, the cell itself becomes the executioner, eliminating the threat.
But here’s where it gets controversial: Until now, most molecular glues have been discovered by sheer luck, limiting their potential as widespread treatments. This hit-or-miss approach has left many in the scientific community skeptical about their scalability. Enter a revolutionary new method developed by the teams of Georg Winter (AITHYRA Research Institute and CeMM Research Center) and Michael Erb (Scripps Research Institute). Their approach combines large-scale chemistry with cell-based screening, transforming the discovery process from a game of chance into a systematic science.
Starting with a small molecule that binds to a target protein, the researchers created thousands of chemical variants by attaching different molecular building blocks. Each variant subtly alters the protein’s surface, potentially unlocking new interactions. And this is the part most people miss: These compounds were tested directly in living cells, without purification, using a sensitive assay that detects protein degradation in real time. This allowed for rapid identification of effective compounds from an enormous chemical library.
“Our method merges high-throughput chemistry with functional testing in cells,” explains Miquel Muñoz i Ordoño, a PhD student in Winter’s lab. “This lets us explore chemical diversity on an unprecedented scale while instantly seeing which compounds deliver the desired biological effect.”
To prove their concept, the team targeted ENL, a protein linked to acute leukemia. From thousands of compounds, they identified a molecule that selectively triggers ENL’s degradation in leukemia cells. Further analysis revealed that the compound primarily impacts ENL and its downstream gene programs, significantly slowing the growth of ENL-dependent leukemia cells. Interestingly, the compound operates through a cooperative mechanism typical of molecular glues: it first binds to ENL, then creates a new interaction surface to recruit a cellular ubiquitin ligase, marking ENL for destruction.
“This cooperative action is what makes molecular glues so powerful and selective,” Winter notes. “The compound only activates in the right molecular context, minimizing unwanted side effects.”
Published in Nature Chemical Biology (DOI: 10.1038/s41589-025-02137-2), the study goes beyond ENL, offering a broadly applicable strategy for discovering molecular glues. By merging high-throughput chemistry with functional cell screening, the researchers have turned a serendipitous process into a systematic workflow.
“Our aim is to make proximity-inducing drugs discoverable in a rational, scalable way,” Winter adds. “Long term, this could unlock therapeutic opportunities for proteins once deemed untreatable.”
But here’s the question that sparks debate: As we move toward systematic discovery of molecular glues, how will we balance the promise of targeted therapies with the ethical implications of manipulating cellular processes? Could this approach inadvertently lead to unforeseen consequences? We’d love to hear your thoughts in the comments below. Let’s keep the conversation going!
